KBio aims to create a new generation of biologics using its plant-based platform that has demonstrated the ability to create drug candidates at a fraction of the time and cost of conventional platforms. The Company is focused on developing novel product candidates in two core areas: 1) Antibody therapies for areas of high unmet need; and 2) Pandemic preparedness and response using its plant-based production system to create antibodies and vaccines in shorter timeframes than industry norms.
 
Formed in December 2021, KBio is a subsidiary of BAT with operations in the UK and U.S. 

KBio

Patrick Doyle

Travis Newton

Oscar Guzmán, M.D. CP

Teams at KBio

Science and Engineering

Leadership Team